A new clinical trial involving teriparatide was updated on July 16, 2026. The study, titled "A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants," is registered under identifier NCT07497503. It is listed as a Phase 1 trial. According to the registry, the trial's current status is recruiting. Forsteo is a branded formulation of teriparatide, and this study is comparing it with B-3E07 in healthy adult female participants. No outcomes, safety findings, or efficacy results have been reported as part of this update. The trial record reflects only the recruitment status and study design details as registered. Further information, including eligibility criteria and study design specifics, can be found through the official trial listing. Readers interested in teriparatide's background, approved uses, and regulatory status can consult the compound overview for additional context.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07497503"]